首页> 外文OA文献 >A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

【2h】

A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

机译：抗CD37单克隆抗体，BI 836826的相位IB，开放标签，剂量升级试验，与吉西他滨和Oxaliplatin组合在复发/难治性弥漫性大B细胞淋巴瘤患者中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Monica Balzarotti; Massimo Magagnoli; Miguel Ángel Canales; Paolo Corradini; Carlos Grande; Juan-Manuel Sancho; Francesco Zaja; Anne-Marie Quinson; Valérie Belsack; Daniela Maier; Carmelo Carlo-Stella;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial [J] . Raymund Buhmann, Stanglmaier Michael, Hess Juergen, Journal of Translational Medicine . 2013,第1期

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案，非随机，不受控制，剂量递增的I / II试验阶段
2. A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) [J] . Goy Andre, Ramchandren Radhakrishnan, Ghosh Nilanjan, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：复发性或难治性（R / R）弥漫性大B细胞淋巴瘤（DLBCL）患者中依鲁替尼联合来那度胺和利妥昔单抗的多中心开放标签1b / 2期研究
3. A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) [J] . Goy Andre, Ramchandren Radhakrishnan, Ghosh Nilanjan, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：复发性或难治性（R / R）弥漫性大B细胞淋巴瘤（DLBCL）患者中依鲁替尼联合来那度胺和利妥昔单抗的多中心开放标签1b / 2期研究
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial [O] . Nicolas Mounier, Taoufik El Gnaoui, Hervé Tilly, 2013

机译：利妥昔单抗联合吉西他滨和奥沙利铂用于难治性/复发性弥漫性大B细胞淋巴瘤患者不适合大剂量治疗。 II期淋巴瘤研究协会试验
6. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II lymphoma study Association trial [O] . Mounier, N., El Gnaoui, T., Tilly, H., 2013

机译：利妥昔单抗联合吉西他滨和奥沙利铂用于难治性/复发性弥漫性大B细胞淋巴瘤患者，不适合大剂量治疗。 II期淋巴瘤研究协会试验

A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

著录项

引文网络

相似文献

相关主题

期刊订阅